Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XOMA Gets Milestone Payment From AVEO Pharma
XOMA and AVEO said that the milestone payment resulted from AVEO’s recent commencement of AV-299 Phase 2 clinical trial to evaluate its antibody for the treatment of non-small
XOMA and AVEO said that the milestone payment resulted from AVEO’s recent commencement of AV-299 Phase 2 clinical trial to evaluate its antibody for the treatment of non-small
iCo Therapeutics said that iCo-007 is designed and discovered by ISIS Pharmaceuticals, iCo-007 is a second-generation antisense drug targeting c-Raf kinase for the treatment of DME and diabetic
Boston Scientific said that EZ Stent System is an intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms. Neuroform EZ Stent
Colorcon said that the addition of the film coating products from this acquisition complement its existing range of one-step, tablet film coatings for pharmaceutical solid oral dose development.
Albemarle has posted a net income of $81,751 for the second quarter 2010, or $0.89 per diluted share, compared to $38,493, or $0.42 per diluted share for the
Sensient has posted a net income of $ 28,685 for the second quarter 2010, or $0.58 per diluted share, compared to $25,819, or $0.53per diluted share, for the
With these launches the company plans to expand its product selection in order to offer a more comprehensive range of amino acids. Amino’s current line-up of amino acids
Oracle claimed that the new solution helps pharmaceutical manufacturers facilitate compliance with emerging electronic pedigree (ePedigree) initiatives and regulatory requirements, reduce business and reputational risk associated with the
X-Body Biosciences and SRU Biosystems said that they have jointly developed a new BIND Biosensor design for use with the commercially available SRU BIND Reader that results in
According to Boehringer Ingelheim’s VERxVE randomised study 400mg QD Nevirapine extended release formulation (Viramune XR) demonstrated adequate trough drug exposure through 48 weeks, and efficacy was consistent across